Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Exclusion Criteria

• •Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
• •Uncontrolled and/or active systemic infection (viral, bacterial or fungal)
• •Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.
• •Child class B or C cirrhosis
• •Treatment with any of the following within 7 days prior to the first dose of cirmtuzumab:
• •Steroid therapy for anti-neoplastic intent
• •Biologic agent (monoclonal antibody) within 30 days for anti-neoplastic intent.
• •Chemotherapy (purine analog or alkylating agent) or target small molecule agent within 14 days or 5 half-lives (whichever is shorter), or has not recovered to less than CTCAE grade 2 clinically significant adverse effect(s)/toxicity(s) of previous therapy.
• •CLL therapy, aside from venetoclax.
• •History of other malignancy that could affect compliance with the protocol or interpretation of results (example: patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are generally eligible.)
• •Women who are pregnant or lactating